Devices descending from K072038
26 later devices reach Vitek 2 Gram Negative Levofloxacin through their predicates, nearest generation first.
| Generation | Number | Device | Applicant | Decided | Own descendants | Recalls |
|---|---|---|---|---|---|---|
| +1 | K222378 | VITEK 2 AST-Gram Negative Levofloxacin (</=0.125 ->/=8 ug/mL) | bioMerieux, Inc. | 2023 | 0 | — |
| +1 | K082346 | Vitek 2 Gram Negative Doripenem | bioMerieux, Inc. | 2009 | 22 | — |
| +1 | K080107 | Vitek 2 Gram Negative Piperacillin/Tazobactam | bioMerieux, Inc. | 2008 | 0 | 114 |
| +1 | K073083 | Vitek 2 Gram Negative Piperacillin | bioMerieux, Inc. | 2007 | 0 | — |
| +2 | K091899 | Vitek 2 Gram Negative Meropenem | bioMerieux, Inc. | 2009 | 21 | — |
| +3 | K110106 | Vitek 2 Gram Negative Trimethoprim/Sulfamethoazole | bioMerieux, Inc. | 2011 | 0 | — |
| +3 | K103752 | Vitek 2 Systems (PC) 5.02 Software | bioMerieux, Inc. | 2011 | 19 | — |
| +4 | K220546 | Colibrí System | Copan Wasp Srl | 2022 | 2 | — |
| +4 | K121546 | Vitek 2 Gram Negative Doxycycline | bioMerieux, Inc. | 2012 | 15 | — |
| +5 | K223245 | Colibrí | Copan Wasp Srl | 2023 | 1 | — |
| +5 | K162737 | VITEK 2 AST-GN Ciprofloxacin (<=0.06->=4µg/mL) | bioMerieux, Inc. | 2017 | 0 | — |
| +5 | K163637 | BD Phoenix Automated Microbiology System - GN Ceftazidime/avibactam (0.25/4- 32/4ug/mL) | Becton Dickinson & Company | 2017 | 0 | — |
| +5 | K163563 | VITEK 2 AST-GN Gentamicin (<=1 – >=16 µg/mL) | bioMerieux, Inc. | 2017 | 1 | — |
| +5 | K161510 | VTEK 2 AST-GN Ceftolozane/Tazobactam (<=0.25 - >= 32 mcg/mL) | bioMerieux, Inc. | 2017 | 1 | — |
| +5 | K161217 | VITEK 2 Gram Negative Ceftriaxone (<=0.25->=64 ug/mL) | bioMerieux, Inc. | 2017 | 0 | Class I |
| +5 | K161227 | VITEK 2 AST-GN Cefepime (<=0.12->=32 ug/mL) | bioMerieux, Inc. | 2016 | 5 | — |
| +5 | K152075 | VITEK 2 AST-Gram Negative Ertapenem (<=0.12 - >=8 ug/mL) | bioMerieux, Inc. | 2016 | 1 | 1 |
| +6 | K232756 | Colibrí | Copan Wasp Srl | 2023 | 0 | — |
| +6 | K223478 | VITEK® 2 AST-Gram Negative Plazomicin (=0.5 - =16 µg/mL); VITEK® 2 AST-GN Plazomicin… | bioMerieux, Inc. | 2023 | 0 | — |
| +6 | K172944 | VITEK 2 AST-GN Ceftazidime/Avibactam <=0.12 – >=16 µg/mL | bioMerieux, Inc. | 2017 | 0 | 1 |
| +6 | K172731 | VITEK 2 AST-GN Amikacin (<=1 ->=64 ug/mL) | bioMerieux, Inc. | 2017 | 3 | — |
| +6 | K161437 | VITEK 2 AST Gram Negative Cefotaxime (<=0.25 - >=64 ug/mL) | bioMerieux, Inc. | 2017 | 0 | — |
| +6 | K163006 | VITEK 2 AST-GN Tigecycline (<0.5->8 ug/mL) | bioMerieux, Inc. | 2017 | 0 | — |
| +7 | K183415 | VITEK 2 AST-Gram Negative Imipenem (</=0.25->= 16 ug/mL) | bioMerieux, Inc. | 2019 | 2 | 1 |
| +8 | K193572 | VITEK 2 AST-Gram Negative Imipenem/Relebactam (<=0.25/4 - >=16/4 µg/mL) | bioMerieux, Inc. | 2020 | 1 | — |
| +9 | K211136 | VITEK 2 AST-Gram Negative Imipenem/Relebactam (<0.25/4 - >16/4 ug/ML) | bioMerieux, Inc. | 2021 | 0 | 1 |